MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre review To guage multiple intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Key demo targets have been to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymyositis patients, whilst one of several exp... https://maoecrystal-b24578.blogozz.com/30252130/detailed-notes-on-m3541